Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The WeBinar and e-Portal are sites for physicians. To get samples as well.
http://www.dermasciences.com/elearning-portal/
"Derma Sciences offers a broad range of product solutions for providers of burn care".
http://www.dermasciences.com/products/burn-care/
So then after (all) that when I came across DSCI without any moderators, I jumped at the chance. I never saw what company's product was prescribed. I thought I heard MediHoney in passing, but don't know for sure. Matters not.
My 'personal' interest in this company is that medicinal honey was prescribed for a family member & it stabilized a serious, threatening bed sore when nothing else did. Not heavy-duty antibiotics, etc. "Wow" is what everyone had to say, including the nursing staff. It is like slapping a bacteria Killer directly, right onto a wound. Wound care is what this company has been all about. I love it.
OTC L2 opened with "U" [unpriced quotes].
Everbody seen the Manuka flower and honey bee on the iBox? 3/4 the way down.
Ok. Let's see if these images hold.
Might be a problem elsewhere too. Checking into it. The images are good for our iBox.
ooops. iBox images aren't filling (for me). Anyone else? Going to leave it till I hear from someone. Only one is filling. 1st time in 6 iBoxes they didn't fill pretty quickly.
Manuka Honey is a premium, mono-floral honey which is produced by bees that gather nectar from the flowers that grow on the Manuka bush (also known as Leptospermum scoparium) indigenous to New Zealand. http://www.HoneymarkProducts.com
http://images.search.yahoo.com/images/view?back=http%3A%2F%2Fimages.search.yahoo.com%2Fsearch%2Fimages%3F_adv_prop%3Dimage%26b%3D85%26ni%3D21%26va%3Dderma%2Bsciences%26xargs%3D0%26pstart%3D1%26fr%3Dslv8-att&w=480&h=360&imgurl=i.ytimg.com%2Fvi%2F8TUVRC41m5Q%2F0.jpg&rurl=http%3A%2F%2Fwww.encyclopedia.com%2Fvideo%2FeAdmnmJtJvI-active-manuka-honey-wound-care.aspx&size=14KB&name=Video+About+%7C+En...&p=derma+sciences&oid=4078cfe7460dc437365c86d8e7c17a76&fr2=&no=95&tt=2300&b=85&ni=21&sigr=12hpv7fh0&sigi=110nakgbe&sigb=13mfrc4ga&.crumb=L6nuQQBKv2U
DSCI. iBox under construction.
"If approved, Derma's drug will compete with Johnson & Johnson's Regranex for the treatment of deep neuropathic diabetic foot ulcers.
"We believe our data is stronger than Regranex," Wolfenson said.
the same link:
http://health.yahoo.net/news/s/nm/us_dermasciences
"We certainly do not have the type of money necessary to complete this (late-stage) trial".
They are looking for a partner.
"If approved, DSC127 could rake in up to $500 million in annual sales in the United States alone".
[the 24 week data]"The data will help the company in outlicensing ex-U.S. rights of the drug, codenamed DSC127, to a potential partner, Chief Executive Edward Quilty said in an interview".
Derma's Quilty "..expects to partner the drug by the end of this year or early next year.
Barry Wolfenson, executive vice-president of global marketing & business development, said, "I think the real activity around partnering for this will commence this week as we announce the data and start putting a package together and reaching out to potential partners around the world."
the same link"
http://health.yahoo.net/news/s/nm/us_dermasciences
" expects to partner the drug by the end of this year or early next year.
Barry Wolfenson, executive vice-president of global marketing & business development, said, "I think the real activity around partnering for this will commence this week as we announce the data and start putting a package together and reaching out to potential partners around the world."
http://health.yahoo.net/news/s/nm/us_dermasciences
"MEDIHONEY® dressings, a unique line of dressings containing Active Leptospermum Honey from New Zealand, possess unique qualities that make them ideal for the management of chronic and acute wounds and burns. A strong and growing evidence base – including several large scale randomized controlled studies – have shown that MEDIHONEY® dressings are effective on hard-to-heal wounds and burns, in addition to helping to debride wounds and keeping wound beds clean of necrotic tissue".
"Because they contain a very high percentage of Leptospermum honey, MEDIHONEY® dressings are able to work in the presence of wound fluid, blood, and tissue, thus promoting an optimal healing environment".
http://www.dermasciences.com/products/advanced-wound-care/medihoney/inside-the-u-s/
This is also a 'new volume stock'. Fits my radar. So, I am very interested in DSCI for more than one reason. Based on personal experience, "medicinal honey patch" is a VALUABLE, NEEDED, REAL, Quality of Life product!
Advanced Care facilities, inc hospices, are using the honey patch more and more often. I had a family member had honey patches applied to a really dangerous bed sore. The honey patch worked when not one thing else did. !!!
•DSCI stock is undervalued
?Current market cap is substantially less than 2009 sales
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10208
"With regard to China, we maintain our own QA / Management team"
http://www.dermasciences.com/contract-manufacturing/capabilities-products/
Example: We hire the best people we find, treat them with dignity and respect, and provide an environment in which they can realize their fullest potential and desire for excellence.
http://www.dermasciences.com/contract-manufacturing/quality-policy/
This the quality company EliLilly used to be.
I worked at Lilly as a lab tech in 1969.
Looking in. Very little sentiment on NASDAQ lately.
http://www.nasdaq.com/aspx/sentiment.aspx?symbol=DSCI&selected=DSCI
Ron.. Nice video, i'm looking to establish a position in here shortly!
Thanks for the link.
Tim
DSCI
Everything is coming together for DSCI.
Here's an older video but they are executing
http://www.ustream.tv/recorded/7994431
it has gone up a lot but the market cap is still ridiculously low. dsci is generating $40 million in revenues already yet only has a $70 million market cap. they have 2 510K approvals coming up along with phenomenal results from phase 2. i think this one has a long way to go.
I would be patient and wait for a pullback, its ripped about 200% in less than a month...IB*O people learned that the hard way when they were chasing it at 6$.
I still think DSCI is quite undervalued at this level. Extremely low float and great potential. $25 price target put out yesterday. Adam Feurstein actually likes this one. DSCI already generates $40 million in yearly revenues. Their new product looks like it should be approved in the future. At just 10% market penetration, you are looking at a $300+ million market. Margins are 90%. This product, based on the recent results, will be the best one available for Diabetic wounds so 10% penetration may be on the lower side.
http://www.dermasciences.com
http://finance.yahoo.com/news/Derma-Sciences-Reports-bw-3870462175.html?x=0&.v=1
http://www.thestreet.com/_yahoo/story/10995888/1/biotech-stock-mailbag-derma-sciences.html?cm_ven=YAHOO&cm_cat=FREE&cm_ite=NA
http://www.americanbankingnews.com/2011/02/09/analysts-price-target-changes-for-february-9th-cxo-dis-dsci-emc-fis-flo/
where did you learn to spell?
DSCI $10.36 running liek a skald-d Dogg on short skweeze,, Shorty must be in Big trubble cuz I didnt xxxxpekt to see tha shortcovrring until nexxxxt Tuesday,,
ok I just dumpt haff my remaining Positshun in2 tha ShortCovrr-ing Rally,, and now will let tha rest of tha Free Sharez ride until tha BuyOut by J&J,,, at 40$ dollerz,, in 6 monthz
Shorty jumpt on top of DSCI at 9.5 makin sure we not gunna gitt one of thoze $30-$40 Krazy Moonshot Runz off that 3m Flote
I just took Tha Bet out at $9.1 avg. nn let tha House Munny Free Shaerez ried,, cuz with 3m Flote and DSCI being a BuyOut Kandidate, Id say these sharez are worth alot more than $9, prolly kloser to $20-$30.
Ther will prolly be a shortcovering run in about 3 dayz too.
Derma's foot-wound drug meets trial goal; shares jump
Derma Sciences Inc
DSCI.O
$8.67
+2.00+29.99%
11:02am EST
Thu Feb 3, 2011 10:44am EST
* Says high dose meets mid-stage trial goal
* CEO sees launch by 2014-15
* Sees $200-$300 mln/yr worldwide sales for the drug
* Partner talks could bear fruit within 6-9 months - CEO
* Shares rise more than 42 pct
Feb 3 (Reuters) - Derma Sciences Inc (DSCI.O) said the high dose of its experimental diabetic foot-wound drug met the main goal of a mid-stage study, raising chances of the company finding a partner for the compound and sending its shares up 42 percent to a new year high.
Potential partners could emerge within six to nine months, its Chief Executive Edward Quilty told Reuters, adding that expected to launch in 2014-15, the drug could bill about $200-$300 million per year in worldwide sales. [ID:nSGE712099]
The Princeton, New Jersey-based company is developing the drug, DSC127, for the treatment of diabetic foot ulcers.
Derma Sciences, which specializes in wound-care products, was testing the drug in two dose strengths and one placebo-controlled arm.
The company said the high dose of the drug exceeded the trial's main goal of improving complete healing of wounds within the 12-week duration by at least 15 percentage points, against a dummy drug.
However, patients receiving the low dose arm failed to show an improvement of 15 percentage points in complete healing of wounds, against a dummy drug.
"The trial was not powered for statistical significance. However, there was a statistically significant improvement in the rate of ulcer depth reduction in the Per-Protocol high-dose population through 12 weeks of treatment compared with the control arm," the company said.
The drug was well-tolerated and there were no significant adverse events associated with the treatment.
Derma shares were up 31 percent at $8.70 in Morning trade on Thursday on Nasdaq. They touched $9.50 in early trade.
The shares had lost about a quarter of their value over the last year. (Reporting by Anand Basu and Vidya L Nathan in Bangalore; Editing by Gopakumar Warrier)
Great news this AM. To da moon
Derma Sciences to Hold Conference Call to Discuss Results from Phase 2 DSC127 Trial in Diabetic Foot Ulcers February 3
Press Release Source: Derma Sciences, Inc. On Wednesday February 2, 2011, 4:05 pm EST
PRINCETON, N.J.--(BUSINESS WIRE)-- Derma Sciences, Inc. (Nasdaq:DSCI - News), a medical device and pharmaceutical company focused on advanced wound care, will issue a news release announcing top-line efficacy results from its Phase 2 trial with DSC127 in diabetic foot ulcers at 7:00 a.m. Eastern time Thursday, February 3 and will hold a conference call to discuss those results at 10:00 a.m. Eastern time that same day.
To participate in the conference call, from the U.S. please dial (888) 563-6275 and from outside the U.S. please dial (706) 634-7417. All listeners should provide passcode 41467730. Individuals interested in listening to the live conference call via the Internet may do so by logging onto the Company’s website, www.dermasciences.com.
Following the completion of the conference call, a replay will be available through February 10, 2011, and can be accessed by dialing (800) 642-1687 from the U.S. or (706) 645-9291 from outside of the U.S. All listeners should provide passcode 41467730. The webcast will also be available on the Company’s website for 30 days.
A10shun incumming ihub DEPO fda playurz! ReMINDer:
DEPO: 7-8
DSCI: 7-(10-40)
Dont set Ur Sites Low Hear at DSCI liek at tha Measly $1 Payout at DEPO imo,,, Remembbrr, Tha 3m Flote at DSCI iz xxxxaktly wutt tha MOMO nn Hedgie playurz rr L(o)(o)king For,,,
In a Frothy Markitt,, Tha Gap Up Hear cudd be $10, $15, maybe $20..
just for startrrz... Gapp nn Runn baby
If U Fruntlode for 7 nn sell at 8 for a kwik Bukk Liek at DEPO , urr prolly gunna hafta just Ried Tha Pine nn Watch az all tha Playurz stuff they Pokitz full with all tha Munny On Tha Tabull that U Missd... at DSCI.. Maybe 3-5 baggz Full,,
Tikka tikkaaa
Itza NoBrainrr!! I luv this play for kwik flip nexxxxt weak, AAAAAND also for 6 month buyout play. Several groups + shorty manipUlating this 3m Flote stokk HUGH in advance of tha MEGA HUGH gap up to 10-12$ nexxxxt weak,,
Then aftrr tha Resultz,, prolly a Bidding war brew-ing.. cuz Evry buddy knowz J&J will NOT let DSCI even gitt a chance to go to Phaze 3,, or risk letting a FDA Phaze 3 drug fall into tha handz of a Kompetitor...
Prediktshun: J & J Buyout at 40$ hear at DSCI
MAJOR NEWS COMING WITHIN 2 WEEKS .MARKET CAP OF 46 MILLION IS A BIG JOKE .
What's Making News At Derma Sciences?
1/26/2011 5:47 AM ET
(RTTNews) - Shares of Derma Sciences Inc. (DSCI: News ), a medical device / pharmaceutical company focused on wound care, have gained over 50 percent in the last five days as investors eye a couple of near-term catalysts.
The company is developing a drug for wound healing and scar reduction - DSC127, which is under a phase II study on diabetic foot ulcer healing. The phase 1 trial with DSC127 was successfully completed in 2007, and the initial key efficacy results from the phase II trial are expected by the end of this month.
In animal studies, DSC127 has shown to be significantly more effective than Johnson & Johnson's Regranex, the only FDA-approved drug for wound healing.
The total market for accelerated healing and scar reduction drug is estimated at $30 billion and DSC127 has blockbuster potential, according to Derma Sciences. Regranex, which bears a black box warning as it is linked to an increased risk of cancer death, has annual sales of $100 million.
The company will be evaluating future development and partnering opportunities for DSC127 after reporting the top line phase II results. Derma Sciences was also awarded $244,479 from the U.S. government under the Patient Protection and Affordable Care Act related to the development of DSC127.
Derma Sciences, which is focused on wound care products, has three primary business segments - Advanced Wound Care, Basic Wound Care and Drug Development.
The Advanced Wound Care segment includes proprietary dressings like MEDIHONEY, BIOGUARD, XTRASORB, MedEfficiency and ALGICELL. This is a high-growth, high-margins segment. Last July, the company submitted a 510(k) application to the FDA for MEDIHONEY Gel wound & burn dressing and is awaiting the regulatory agency's decision.
The Basic Wound Care segment is the company's core business, generating over 80 percent of current total revenue. This segment includes both branded and private-label/OEM bandages, gauze-based dressings, wound closure strips, and first aid products.
For the nine months ended September 30, 2010 net sales were up 18 percent to $41.17 million. Net loss for the period widened to $1.97 million or $0.31 per share from $1.18 million or $0.23 per share in 2009. At September 30, 2010, the company had cash and cash equivalents of $409,505 compared to $243,524 in December 31, 2009.
DSCI underwent a 1-for-8 reverse split, which became effective on February 1, 2010. The stock, which has thus far hit a 52-week low of $0.73 and a 52-week high of $9.00, closed Tuesday's trading at $6.98, up 5.28 percent.
Jump to 12-15$ Coming
Blockbuster PII data coming within 2 Weeks .BUY OR MISS THE OPPORTUNITY
Still a great Opportunity
Do your dd quickly before the stock jumping over 10$
Great Article out ...This unknown gem is still wayyyy Undervalued .Market Cap of $ 45 M is a big joke for this great Company .
http://www.rttnews.com/Content/TopStories.aspx?Id=1535906
What's Making News At Derma Sciences?
1/26/2011 5:47 AM ET
(RTTNews) - Shares of Derma Sciences Inc. (DSCI: News ), a medical device / pharmaceutical company focused on wound care, have gained over 50 percent in the last five days as investors eye a couple of near-term catalysts.
The company is developing a drug for wound healing and scar reduction - DSC127, which is under a phase II study on diabetic foot ulcer healing. The phase 1 trial with DSC127 was successfully completed in 2007, and the initial key efficacy results from the phase II trial are expected by the end of this month.
In animal studies, DSC127 has shown to be significantly more effective than Johnson & Johnson's Regranex, the only FDA-approved drug for wound healing.
The total market for accelerated healing and scar reduction drug is estimated at $30 billion and DSC127 has blockbuster potential, according to Derma Sciences. Regranex, which bears a black box warning as it is linked to an increased risk of cancer death, has annual sales of $100 million.
The company will be evaluating future development and partnering opportunities for DSC127 after reporting the top line phase II results. Derma Sciences was also awarded $244,479 from the U.S. government under the Patient Protection and Affordable Care Act related to the development of DSC127.
Derma Sciences, which is focused on wound care products, has three primary business segments - Advanced Wound Care, Basic Wound Care and Drug Development.
The Advanced Wound Care segment includes proprietary dressings like MEDIHONEY, BIOGUARD, XTRASORB, MedEfficiency and ALGICELL. This is a high-growth, high-margins segment. Last July, the company submitted a 510(k) application to the FDA for MEDIHONEY Gel wound & burn dressing and is awaiting the regulatory agency's decision.
The Basic Wound Care segment is the company's core business, generating over 80 percent of current total revenue. This segment includes both branded and private-label/OEM bandages, gauze-based dressings, wound closure strips, and first aid products.
For the nine months ended September 30, 2010 net sales were up 18 percent to $41.17 million. Net loss for the period widened to $1.97 million or $0.31 per share from $1.18 million or $0.23 per share in 2009. At September 30, 2010, the company had cash and cash equivalents of $409,505 compared to $243,524 in December 31, 2009.
DSCI underwent a 1-for-8 reverse split, which became effective on February 1, 2010. The stock, which has thus far hit a 52-week low of $0.73 and a 52-week high of $9.00, closed Tuesday's trading at $6.98, up 5.28 percent.
DSCI was a $200+ stock a few years ago ...
and it has really good chance to move back up to that level with our 1.5 Mil low float .
DSC127 THE MULTIPLE BLOCKBUSTER IS THE REASON WHY WE COULD SEE THE OLD HIGHS AGAIN .MAJOR PHASE 2 RESULTS COMING THIS OR NEXT WEEK AND THE COMPANY IS VERY OPTIMISTIC ABOUT THE RESULTS .A POTENTIAL PARTNERSHIP FOR DSC127 COULD BRING UPFRONT PAYMENTS WHICH WILL BE MUCH HIGHER THAN CURRENT MARKET CAP .AGAIN THIS IS A PURE GOLDMINE !!! GL
KEY PRODUCT UNDER DEVELOPMENT
DSDSC127 (angiotensin analog)
Novel angiotensin analog for use in wound healing and scar reduction. Successfully completed a phase I trial in 4Q07, and presently undergoing phase II trials to assess safety and efficacy of DSC127 on healing diabetic ulcers. Results from the phase II trials are expected in 4Q10.
* "Blockbuster" potential - with applications in the following markets:
o $10 billion chronic wound market
o $8 billion scar prevention/reduction market
o $6 billion burn market
o $6 billion radiation and other wound markets
* Limited competition - Systagenix's Regranex is the only FDA-approved drug for wound healing. (Systegenix is formerly Johnson & Johnson's Chronic Wound Care division.)
o Regranex has a black box warning and has achieved sales exceeding $100M per year
Derma Sciences presents a unique opportunity in the micro-cap biomed space since it has a core business focused on would care which generates revenue and operating cash flow to fund the Phase 2 clinical development for a treatment (DC127) that targets a prescription drug market that is about 5X the Company’s current market cap (based on Regranex sales of $150M). In addition, pre-clinical data suggests DC127 may offer both safety and efficacy advantages over Regranex and the licensing deal by Shire for a scar prevention treatment that included a $75M up-front payment suggests Derma Sciences has the potential to secure a licensing deal that could include an up-front cash payment in excess of its current market cap of around $30M.
We could see $10+ by Friday without News .Fasten your seat belts !
We have a very very BULLISH CHART and no real resistance below $10
http://www.barchart.com/opinions/stocks/DSCI
Trader`s cheat sheet info
http://www.barchart.com/cheatsheet.php?sym=DSCI
http://www.stoxline.com/quote.php?symbol=dsci
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
Watch Video´s ...We have the cure for Diabetic Wounds a Blockbuster Market .
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10309
Still time to Buy this sleeping giant
Your welcome jay
Looking great ! Thanks Bio...
This very low float GOLDMINE could move to over 15$ in no time .DSCI is still under Radar,the highest Volume in the history of this stock is only 120K means once investors discover this stock it will move up at the speed of light with 1.5-2 Mil shares on the float .A Partnering for Blockbuster candidate DSC127 could bring huge upfront cash payment which could be much higher than current Market Cap (see post below) .DID YOU REALISE THE FANTASTIC POTENTIAL IN DSCI ??
A lot of MAJOR news coming very soon to push this GOLDMINE to ALL TIME HIGHS .
Market Cap: 34.6 MIL$
Price: 5.28 $
Shares Out: 6.5 MIL // 3 MIL Shares held by Insiders
Short Data : Only 3154 Shares
Upcoming Milestones for 1Q 2011 (New dates below are from the Company ,I got a response from IR yesterday )
http://www.wsw.com/webcast/maxim3/dsci/2__Slide21.JPG
Phase 2 results for Blockbuster Candidate DSC127 this Week or first Week in Feb 2011
Expect FDA 510k Clearance for Medihoney gel 4Q10 = VERY SOON
Submit another 510K Application to FDA for Medihoney Hydro in Jan or early Feb 2011
PartnerShip with upfront cash payment for Potential Blockbuster DSC127
**************************************************************
A MUST READ ..
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10208
KEY PRODUCT UNDER DEVELOPMENT
DSDSC127 (angiotensin analog)
Novel angiotensin analog for use in wound healing and scar reduction. Successfully completed a phase I trial in 4Q07, and presently undergoing phase II trials to assess safety and efficacy of DSC127 on healing diabetic ulcers. Results from the phase II trials are expected in 4Q10.
* "Blockbuster" potential - with applications in the following markets:
o $10 billion chronic wound market
o $8 billion scar prevention/reduction market
o $6 billion burn market
o $6 billion radiation and other wound markets
* Limited competition - Systagenix's Regranex is the only FDA-approved drug for wound healing. (Systegenix is formerly Johnson & Johnson's Chronic Wound Care division.)
o Regranex has a black box warning and has achieved sales exceeding $100M per year
*************************************************************
Derma Sciences presents a unique opportunity in the micro-cap biomed space since it has a core business focused on would care which generates revenue and operating cash flow to fund the Phase 2 clinical development for a treatment (DC127) that targets a prescription drug market that is about 5X the Company’s current market cap (based on Regranex sales of $150M). In addition, pre-clinical data suggests DC127 may offer both safety and efficacy advantages over Regranex and the licensing deal by Shire for a scar prevention treatment that included a $75M up-front payment suggests Derma Sciences has the potential to secure a licensing deal that could include an up-front cash payment in excess of its current market cap of around $30M.
**************************************************************
Watch Videos about their great Products !
http://www.ir.dermasciences.com/profiles/investor/fullpage.asp?f=1&BzID=1109&to=cp&Nav=0&LangID=1&s=302&ID=10309
Thanks BioSpecialist... I got in a $5.00 and looking good.
Followers
|
16
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
181
|
Created
|
08/14/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |